Date post: | 08-May-2015 |
Category: |
Health & Medicine |
Upload: | redchip-companies-inc |
View: | 614 times |
Download: | 1 times |
Empowering Personalized Cancer Treatment
Summer 2014
062314
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 2
Forward-Looking Statement
This presentation contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development and potential opportunities for Cancer
Genetics, Inc. products and services or Gentris, Inc. products and services., along with other
statements about the future expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that are not historical fact
(including, but not limited to, statements that contain words such as "will," "believes," "plans,"
"anticipates," "expects," "estimates") should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent
in the development and/or commercialization of potential products, risks of cancellation of customer
contracts or discontinuance of trials, risks that we will not reach agreement on definitive acquisition
agreements with Gentris, or that the Gentris and/or BioServe transactions will not close or, if either or
both closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials
or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property
rights and other risks discussed in the Company's Form 10-K for the year ended December 31, 2013
and 10-Q for the quarter ended March 31, 2014 along with other filings with the Securities and
Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer
Genetics disclaims any obligation to update these forward-looking statements.
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 3
2013 Was a Year of Significant Progress and 2014 Shows Continued Success
54% full year revenue growth 2013 over 2012 and 45% growth Q1, 2014 over Q1, 2013.
Test volume grew 63% to 10,771 tests in 2013 over 2012 and 45% to 2,772 tests in Q1, 2014 over Q1, 2013.
Tripled Gross-Profit Margins to 26% in 2013.
Closed 2 follow-on offerings on NASDAQ totaling ~$60+ Million.
Launched 6 proprietary genomic-based diagnostic tests for lymphomas (CLL/SLL, DLBCL, FL, MCL), kidney cancer and cervical
cancer.
Launched the CALR mutation analysis test targeting ~3 Million patients in the US with MPN.
Received 3 patent awards covering CGI’s diagnostics for hematologic and kidney cancers.
Expanded key biopharma relationships with Gilead and Roche driving adoption of CGI’s genomic tests nationally and
internationally.
Progressive advancements to the management team and board of directors with
experienced and seasoned industry leaders.
Expanded collaborations and partnerships with world-class institutions including
J.V. with Mayo Clinic in Generation Sequencing: OncoSpire Genomics.
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 4
Molecular Diagnostics are Changing our Understanding of Cancer While Providing New Tools to Diagnose & Treat Patients
Our unique focus & approach supports the entire cancer care continuum
Personalize
therapeutic plan and
treatment options
DIAGNOSIS PROGNOSIS THERANOSIS
Assist in patient
outcome and disease
management
What drug(s) to give, how
much, and when?
What are my survival
prospects?
Do I have cancer and
what type?
Use genomics to provide
an accurate and definitive
typing of the cancer
Proprietary Products Focused Oncology Lab Comprehensive Report
Integrated Molecular Diagnostic Testing Brings Benefits
Across the Entire Oncology Ecosystem
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 5
CGI’s Mission is to Personalize and Improve the Success Rate in Cancer Treatment
Integrating & Delivering Genomic Information About a Patient’s Cancer
Can Improve Care & Reduce Cost
Phenotypic &
Physical Examination
Morphologic &
Pathological Analysis
Large & Multiple
Specimens Required
Significant Delays to
Treatment
Traditional Approach
Biomarkers and
Companion Diagnostics
Genomic Analysis &
Proprietary Algorithms
Reduced Size and
Number of Specimens
Improved Diagnoses &
Treatment Plans
Our Approach: Personalized Medicine
Target For Tomorrow
25%
Situation Today Source: Clinical Trends in Molecular Medicine, Vol. 7, Issue 5
100%
Success Rate Target Success Rate
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 6
The Acquisitions of BioServe India and Gentris Corporation Provide Significant Market Upside & Improve CGI’s Competitive Position
• Access to high-growth Indian diagnostics
market – projected to grow at 15-20% per
annum for the next decade.
• Accelerates next-generation sequencing
development and validation of targeted hot
spot oncology panels.
• Cost-effective expansion of genomic
analysis & informatics capabilities with state
of-the-art 14,000 sq. foot lab.
BioServe India
• Growth potential in integrating our oncology-
focused testing capabilities with Gentris’
high-value contracts.
• Expansion of Gentris’ capabilities and
portfolio to include oncology-focused
pharmacogenomics services.
• 24,000 sq. foot lab space (CLIA/CAP/GLP)
with NGS, genotyping, and gene expression
test capabilities.
Gentris Corporation
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 7
Unique, Scalable and Multifaceted Business Model With A Focus On Providing A Complete Solution
Suite of Products and Services Provides Multiple Growth Drivers and Value to Multiple Parties:
Clinical Community, Biopharma & Medtech
CLINICAL SERVICES
Differentiated and complete
disease-focused solutions
Superior turnaround times
World-class expertise in
genomics and cytogenetics
Serving community hospitals and
labs through unique Expand Dx™
program
BIOPHARMA PARTNERSHIPS
Biomarker and companion
diagnostic development
World-class genomics and
bioinformatics
Drug-specific and cancer-
specific assays
Comprehensive focus in
hematologic and urogenital
cancers
PROPRIETARY PRODUCTS
Proprietary molecular
diagnostics & FISH probes
Clinically validated
IP-protected
Sold globally
Probe manufacturing leverages
low-cost, high scale facility in
India
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 8
Our Target Markets in Oncology Testing Comprise Over 615,000 New Lives Annually in the U.S.
Ability to Impact Over 615,000 New Lives Annually in the U.S.
Source: American Cancer Society
156,420 2014 Estimated New Cases
(U.S.)
Death Rate 35%
Hematological: Lymphoma, Leukemia, M. Myeloma
371,610 2014 Estimated New Cases
(U.S.)
Death Rate 16%
Urogenital: Kidney, Bladder & Prostate
86,970 2014 Estimated New Cases
(U.S.)
Death Rate 31%
Gynecological: Cervical, Endometrial & Ovarian
6 Products Launched in Target Segments
Over $6Bn in Annual U.S. Spend on Lab Testing In These Categories
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 9
6 Proprietary Diagnostic Products Commercially Launched & In Market
Incidence Indication
Lymphoma & Leukemia Microarrays (MatBA®)
106,770 (Annual New Cases, Global)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
142,360 (Annual New Cases, Global)
Diffuse Large B-Cell Lymphoma
62,300 (Annual New Cases, Global)
Follicular Lymphoma
17,795 (Annual New Cases, Global)
Mantle Cell Lymphoma
Kidney Cancer Microarray (UroGenRA®)
274,000 (Annual New Cases, Global)
Kidney Cancer
Cervical Cancer DNA-FISH Probe (FHACT®)
1,750,000 (Annual New Cases, US)
HPV+ Low Grade Cervical Lesions
Over 2.3 Mn Combined Annual New Cases Globally
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 10
Product Pipeline
Research &
Discovery
Clinical
Development
Commercial
Development
Launch &
Market Entry
Indication
Development Stage
Lymphoma & Leukemia Microarrays (MatBA®)
Multiple Myeloma
Bladder and Prostate Cancer Microarrays (UroGenRA®)
Bladder Cancer
Prostate Cancer
HPV-Associated Cancer DNA-FISH Probe (FHACT®)
Head & Neck Cancer
Urogenital Cancer Microarrays (UGenRA™)
Cervical Cancer
Endometrial Cancer
Ovarian Cancer
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 11
Despite Improved Cancer Care, Case Numbers for Hematologic Cancers are Still Rising
Genomics-Based Tests like MatBA® are Critical and Improve
the Management and Cost of Hematologic Cancers
Source: Genzyme & Nature Source: National Cancer Institute, National Center for Health Statistics, SEER
Dataset of Incidence & Mortality, FDA
1 2 5 12
89
100 80 60 30 2
Number of Years Ago
11.1 12.6
15.5
18.5 20.0 19.7
20.5 21.2
5.6 6.2 7.1
7.9 8.7 8.2
6.9 7.3
1975 1980 1985 1990 1995 2000 2005 2010
Incidence Rate Survival Rate
Identified Leukemia & Lymphoma Subtypes Incidence & Survival Rates for NHLs (US Only, per 100,000)
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 12
MatBA®-CLL/SLL Improves Risk Stratification & Outcome Prediction
Validated in Collaboration w/ Dr. Kanti Rai & Dr. Nicholas Chiorazzi (NSLIJ); 2 Datasets, 322 specimens
Additional Validations being conducted w/ HUMC & Dana Farber; 2 Cohorts, 350+ specimens
█ Favorable
█ Intermediate
█ Unfavorable
█ Favorable/
Intermediate
(no distinction)
38% of cases in our study have
a favorable prognosis falling
under "watch & wait" approach.
8% of cases with unfavorable
prognosis missed by FISH and
caught using MatBA®-CLL/SLL.
Impact on therapy selection &
clinical management of CLL
patients.
Genomic Aberrations Reported
by FISH:
4
Genomic Aberrations Reported
by MatBA®-CLL/SLL:
20
85%
15%
FISH
23%
39%
38%
(Current Method) (CGI Method)
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 13
MatBA® can Group Patients into Risk Groups & Prognostication Classes
MatBA®- CLL / SLL is a diagnostic tool and
prognostic indicator for patient stratification
and improved patient management
Being actively used in clinical care, in clinical trials and in
validation programs with Dana Farber, MSKCC and
HUMC
20 key genetic events/sites classify CLL patients as
having the potential for
Poor outcome = High risk
Intermediate outcome = Intermediate risk
Good outcome = Low risk
Detection of specific genomic imbalance in
CLL/SLL by MatBA®-CLL/SLL correlates
patient risk with time to first treatment
(TTFT) and shorter overall survival (OS)
Patients classified as high risk showed a shorter TTFT
compared to those classified as low or intermediate risk
Patients classified as high risk had significantly shorter OS
times than those classified as low or intermediate risk
Provides additional risk stratification between low and
intermediate risk patients, not currently available in other
tests
Time to First Treatment (TTFT)
Time (months)
Time (months)
Pro
po
rtio
n
Su
rviv
ing
P
rop
ort
ion
Tre
atm
en
t-F
ree
– GOOD (n=74)
– INTERMED (n=107)
– POOR (n=47)
– GOOD (n=74)
– INTERMED (n=107)
– POOR (n=47)
P = 0.090
P = 0.001
P < 0.001
P = 0.010
Overall Survival (OS)
Leukemia & Lymphoma – Houldsworth, et. al Sept. 18, 2013
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 14
UroGenRA®-Kidney Can Guide Management of Patients with Renal Masses and Appropriate Treatment Selection
Clinical Benefits Include Reduction in Number of Highly Invasive Procedures and Time to
Treatment Initiation, and Better Informed Treatment Selection
Development of diagnostic algorithm
>600 RCC malignant subtypes (in-silico: SNP)
>100 malignant and benign renal neoplasms (in-house: aCGH & FISH)
Retrospective in-house FFPE validation (n>190) CCF
100% diagnostic yield
97% diagnostic sensitivity to distinguish benign from malignant renal neoplasms
93% sensitivity to distinguish malignant RCC subtypes
C. Magi-Galluzzi and E. Klein (Cleveland Clinic)
Prospective ongoing percutaneous core needle biopsy (n>50) MSKCC
Demonstrated ability to diagnose pathologically “unclassifiable” biopsies prior to surgical
intervention
J. Coleman and J. Durack (MSKCC)
PROBLEM
Men and women with renal masses often
undergo unnecessary nephrectomy for
accurate diagnosis and experience delay in
treatment
SOLUTION
UroGenRA® will detect genomic aberrations in a single assay
permitting accurate diagnosis (benign vs malignant, and
malignant subtype) guiding appropriate management and
treatment strategies
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 15
FHACT® - A New Genomic Aid In The Screening & Management Of Cervical Cancer
FHACT® Provides Critical Information Which Reduces
Unnecessary and Costly Colposcopies
Cervical cancer effects nearly 500,000 women globally each year with
nearly 80% in developing countries.
Today, all these women are
referred for colposcopy.
Women with abnormal or unclear Pap smears
55 Million Pap smears per year
3.5 Million Pap smears come back
as unclear/abnormal
2 Million biopsies performed
12,000 cases of cervical cancer
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 16
FHACT® Provides Information for Developing Treatment Plans Potentially Reducing Healthcare Costs & Procedures
FHACT® is the Only 4 Color FISH Probe that can be Used for Cervical Cancer Screening
as Additional Testing Before Referral for Colposcopy
Global Validation Partners Genomic Amplification by Disease Category
Source: P. Luhn, J. Houldsworth, et al., Gynecologic Oncology (2013)
5 10 19 20
0
20
40
60
80 ptrend = 0.01
6 9 9 20
0
20
40
60
80 ptrend = 0.02
6 9 7 12 0
20
40
60
80 ptrend = 0.03
3 8 12 12 0
20
40
60 ptrend = 0.001
<CIN2
& NLIM
(n=11)
<CIN2
& LSIL
(n=20)
CIN2
&/or HSIL
(n=10)
CIN3+
(n=7)
<CIN2
& NLIM
(n=11)
<CIN2
& LSIL
(n=20)
CIN2
&/or HSIL
(n=10)
CIN3+
(n=7)
FHACT® detects irreversible changes in
cervical cells caused by HPV.
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 17
Large, Targeted Market Opportunities
Target Markets Commercialization Strategy
Community Hospitals
Regional Cancer Centers
Oncologists and Pathologists
Continue to growing sales force that calls on hospitals
and regional laboratories
Plan development of national footprint through Expand
Dx™
Biotechnology Companies
Pharmaceutical Companies
Leverage clinical infrastructure and proprietary product
portfolio for testing services that support clinical trials
Expand sales emphasis of Select One®
Emerging Markets
Enhance distributor base in select emerging economies
Partner with leading local cancer care providers and
hospitals to provide probes, arrays and clinical services
Collaborate to create and validate microarrays and other
proprietary products
Accelerate launch of large scale studies
Universities and Research Centers
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 18
Unique Service Offering Developed to Enable Community Hospitals to Improve Cancer Outcomes & Treat Patients Locally
Delivers better outcomes to
community hospitals and laboratories
Enables community hospitals to bring
“state-of-the-art” genomic testing to
patients
Brings personalized medicine to the
community hospital vs. just at
academic and teaching hospitals
Allows community hospitals to keep
patients and treat them locally
Improving care and quality is critical to
maintaining reimbursement for
community hospitals
$600,000 - $800,000 USD in Testing
Opportunity on Average per Hospital
Expanding & Developing Cancer Care is a
Top Priority for Hospital CEOs & CFOs
4,000 to 5,000 Community Hospitals
& Laboratories in the U.S.
85% Of All U.S. Cancer Patients are Initially
Diagnosed in Community Hospitals &
Laboratories
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 19
Through Acquisition, Clinical Trial Services Show Strong Growth and Robust Pipeline
Gentris Provides Pharmacogenomic Clinical Trial Services to Several Large Pharma
Companies Including Merck, Novartis, Otsuka, Eisai and Bristol-Myers Squibb
GROWTH IN CGI’s SELECT ONE®
CONTRACTS ($000)
21%
55%
ONCOLOGY DRUGS ASSOCIATED WITH
BIOMARKER(S)
$300
$2,700
$8,500
$14,200
2011 2012 2013 2014
Approximate value of contracts with biotech and pharma clients
2011 2016
Source: Company Analysis and Management Estimates
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 20
Over 6,800 Oncology Trials in the US Aligned with our Core Markets
Number of Open Clinical Trials (U.S.)
1,439 1,453
2,178
1,765
Lymphoma Leukemia Urogenital HPV-Associated
Source: www.clinicaltrials.gov
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 21
Gilead is Currently Using a Comprehensive Panel of CGI Services & Proprietary Products in National & International Trials for
Hematologic Cancers
The Gilead Relationship Exemplifies the Significant Upside Potential of
CGI’s Select One® Offering
Highlights
Comprehensive, biomarker-based patient profiling will help risk stratification and response monitoring
Improved patient profiling will result in improved trial efficacy for Gilead
Testing will occur across several methodologies, including flow cytometry, FISH, sequencing and
mutation assays, and MatBA® microarrays
CGI provides biomarker driven insight regarding patient targeting and potential outcomes
Trials cover both national and international locations with all patient specimens being processed in
Rutherford, New Jersey
CGIX Press Release: Cancer Genetics, Inc. Selected By Gilead Sciences, Inc. to Provide Clinical Trial Services for International Trials in Chronic Lymphocytic Leukemia
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 22
Roche Partnership Expanding Market Presence Internationally
“By expanding our relationship, we are strengthening our ability to provide patients the best
service possible.” Alvaro Soto, Roche Servicios, Central America & Caribbean General Manager
Highlights
CGI provides genomic and biomarker testing services to 14 countries
in Central America and the Caribbean.
CGI won a global RFP to help a strategic personalized medicine initiative for Roche Servicios (Latin
America)
Roche sends all patient samples to the Rutherford facility where they are catalogued and processed
CGI interacts with both Roche and the hospital staff (pathologists, oncologists and nurses) and
supports delivery of reports through an online HIPAA compliant portal
CGI and Roche expanded this relationship in 2013 and will begin developing workshops and training
programs to drive adoption of biomarker-based cancer diagnostics throughout Central America and
the Caribbean
CGI and Roche recently further expanded this relationship with an exclusive multi-year deal in which
CGI will develop a center of excellence for lung cancer testing utilizing Roche’s FDA-Approved
cobas® platform
CGIX Press Release: Cancer Genetics, Inc. selected by Roche Servicios S.A. to provide services for the diagnosis and personalization of oncology treatment
CGIX Press Release: Cancer Genetics, Inc. expands relationship with Roche Servicios S.A.
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 23
Collaborations with Premier Cancer Research Institutions Leading Differentiated Research & Driving Product Adoption
Research Collaboration/
Licensing
Clinical
Services
Partnership
Highlights
Kidney Cancer, DLBCL, MCL & FL
Joint Venture Focused on Oncology & Next
Generation Sequencing
Cervical Cancer
DLBCL
CLL
Cervical Cancer & DLBCL
Cervical Cancer
Kidney Cancer
DLBCL, Head & Neck Cancers
CLL
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 24
Mayo Clinic Joint Venture Investing in the Future – OncoSpire Genomics
The Value and Focus of Next Generation Sequencing is Moving from Platforms to Clinically
Relevant, Disease-Specific Applications
Highlights
JV, based in Rochester, MN, will develop clinical diagnostic products and services on NGS platform(s)
in areas of high clinical need
Three initial projects in key oncology categories selected by the SRC (Scientific Review Committee):
Lung Cancer, Multiple Myeloma, Follicular Lymphoma
CGI commits up to $6 M over initial three year period (2013 to 2015-16 expected)
Mayo commits to “in-kind” services and support, use of facilities, NGS capabilities and access to
biorepository
Joint Venture is exclusive in the project areas selected by CGI & Mayo
Important company update and analyst day held November 22, 2013
Next Generation Sequencing in Oncology
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 25
OncoSpire Genomics Projects are Unique and Have High Value
1.6 million
new cases
200,000
new cases
20,920
new cases
Informed
Discovery
Clinical
Development
Commercial
Development
Market Entry
(with partners)
Lung Cancer
Multiple Myeloma
Follicular Lymphoma
Selected Projects Have Significant Clinical Value & May Yield Multiple Focused
Panels to Become the Standard of Care in NGS-Based Oncology Management
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 26
Strong History of Growth CGI Revenue & Clinical Volume Trends (2009 – 2013)
54% Full Year 2013 Revenue Growth
$1.67
$2.52
$3.02
$4.30
$6.61
2009 2010 2011 2012 2013
2,321
3,146 3,622
6,610
10,771
2009 2010 2011 2012 2013
Total Revenue ($Mn) Clinical Volume (Tests Processed)
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 27
Strong History of Growth - Revenue & Clinical Volume Trends (Q1 Comparison 2012-2014)
$835
$1,219
$1,430
Q1, 2012 Q1, 2013 Q1, 2014
Total Revenue ($000)
1,610
1,911
2,772
Q1, 2012 Q1, 2013 Q1, 2014
Clinical Volume (Tests Processed)
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 28
Summary Statement of Operations (Q1 Comparison 2012-2014)
Income Statement Item Q1, 2012 Q1, 2013 Q1, 2014
Revenue $835 $1,219 $1,430
Gross Profit 12 149 140
Gross Margin (%) 1.4% 12.2% 9.8%
Research & Development (R&D) 524 491 597
Sales & Marketing (S&M) 340 396 749
General & Administrative (G&A) 936 1,571 2,731
Operating Profit (Loss) (1,788) (2,309) (3,937)
Net Income (Loss) (1,072)
2,360
(2,486)
$ in thousands
Actual 03/31/14
Cash & Cash Equivalents $41,315
Stockholders’ Equity 43,635
$ in thousands
Summary Balance Sheet
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 29
Consistent Focus on Gross Profit Improvements Additional Efforts Focused Operationally in US & India
Gross Profit Margin Highlights of Initiatives
(52%) (39%) (3%)
9%
26%
(1,000)
(800)
(600)
(400)
(200)
0
200
400
600
800
2009
2010
2011
2012 2013
$ in T
housands
Decrease CGI Costs for
Development & Services
Migrate DNA manufacture and
NT Kits for CGI probes
Develop remove G-Band analysis
capability
Develop remote FHACT®
analysis capabilities
Move entire probe manufacturing
& assembly
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 30
Multiple Customer Types Provide Diversified Revenue Mix With Covered Lives Already in Place
Selected Payors
Direct Bill Customer Types
Biotechs
Pharmas
Academic
Cancer Facilities
Community &
Regional Labs
72+ million covered lives through multiple payors:
13%
21% 58%
3% 5%
Medicare
3rd Party
Insurance Companies,
Hospitals
& Care
Facilities
Payor Revenue Mix 2013
Reimbursement Based Direct Bill / Pay Based
3rd Party Insurance
Medicare Grants
2013
Probes
Companies, Hospitals
& Care Facilities
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 31
Experienced and Focused Management and Boards
Scientific Advisory Board
Andrea Califano, Ph.D. Chairman of the Columbia Initiative for Systems Biology
Associate Director for Bioinformatics, Herbert Irving Comprehensive
Cancer Center
Timothy A. Chan, M.D., Ph.D. Principal Investigator, Human Oncology and Pathogenesis Program
at Memorial Sloan-Kettering Cancer Center
Riccardo Dalla-Favera, M.D. Director, Institute for Cancer Genetics at Columbia University
Hans-Guido Wendel, M.D. Principal Investigator, Cancer Genetics Laboratory at Memorial
Sloan-Kettering Cancer Center
Vundavalli V. Murty, Ph.D. Director, Cancer Cytogenetic Laboratory and Molecular Pathology at
Columbia University
Andrew D. Zelenetz, M.D., Ph.D. Chief of Lymphoma Service and Head of Molecular Hemo-Oncology
Laboratory, Department of Medicine at MSKCC
Raju Chaganti, Ph.D., FACMG Founder
• 35+ years in cancer research; 38 at MSKCC
• Major discoveries in cancer genomics
• Published 350+ articles, 4 patents
Panna Sharma President & CEO
• 15+ years as advisor to global life science & healthcare cos.
• Founded TSG Partners
• Chief Strategy Officer, iXL (IIXL)
Edward J. Sitar Chief Financial Officer & Treasurer
• 30+ yrs in finance & deal making in the healthcare industry
• Healthagen, ActiveHealth Management, Cadent Holding, MIM Corporation
(Bioscrip), Vital Signs, Zenith/Goldline Pharmaceutical, Coopers &
Lybrand
Jane Houldsworth, Ph.D. Vice President of R&D
• 25+ years in translational oncology research
• Published 50+ articles, 4 patents
• NIH grantee
Chairman of the Board, | Keith Brownlie, CPA | Edmund Cannon | Raju Chaganti, Ph.D.
John Pappajohn | Franklyn Prendergast, M.D., Ph.D. | Paul Rothman, M.D. | Panna Sharma
Board of Directors
Officers & Management Team
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 32
Consistent Achievement of Milestones Expected in Coming Quarters
Increasing covered lives market access through
additional payers & health care organizations
Launching multi-marker NGS panel for lymphoid
malignancies
Additional international agreements with life science
tools companies for DNA Probes and product
distribution in key geographies
MatBA® – Next phase of data and results from Dana
Farber and HUMC studies to help support value and
reimbursement
Pursuing CE approval for IVDD use of FHACT® in
E.U.
Additional news on biopharma partners &
relationships
Pursuing additional indications for UroGenRA®-
Kidney microarray
Portfolio and analyst update meeting (June)
Close of BioServe transaction (Q3, 2014)
Accelerating Market Traction – 54% growth during 2013 over 2012
Migrated DNA-FISH Probe Manufacturing to India reducing cost, increasing
capacity and improving operational flexibility
Launched UroGenRA®-Kidney, a unique microarray for kidney cancer
diagnosis in collaboration with MSKCC
Collaborative Study of UroGenRA®-Kidney with Cleveland Clinic
demonstrated 93% diagnostic accuracy
Launched FHACT® outside the U.S. in collaboration with the National
Cancer Institute research publication
Launched FHACT® as an LDT under CLIA in the U.S.
Received CLIA Approval for MatBA®-MCL (Mantle Cell Lymphoma)
Finalized Agreement with Multiplan and Three Rivers which gave us
access to 72+ million covered lives
Launched OncoSpire Genomics – A Next Generation Sequencing Joint
Venture with Mayo Clinic and announced initial set of projects (lung cancer,
multiple myeloma & follicular lymphoma)
Recent
Accomplishments Upcoming Milestones
and Value Drivers
For further information, please contact us at [email protected]
Cancer Genetics, Inc.
Meadows Office Complex
201 Route 17 North
Rutherford, NJ 07070
(201) 528-9200
www.cancergenetics.com
Appendix
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 35
IP Position and Detailed Global Strategy
Strong and growing portfolio in molecular-focused patents for disease
identification and stratification
IP-based on unique algorithms across a broad group of chromosomal regions
Validation of specific clinical endpoints that are associated with
particular disease outcomes or decisions
Filing and maintenance of trademark portfolio
Tool for Diagnosis and Prognosis of Mature B-Cell Neoplasms US Issued Patent 8,580,713 US Issued Patent 8,557,747 Europe 10803548.6 India 6657/DELNP/2012 Canada 2,785,656
Methods of Analyzing Chromosomal Translocations Using Fluorescence In Situ Hybridization (FISH)
US Issued Patent 7,585,964 US Issued Patent 7,964,345 Canada 2,447,320
Panel for the Detection and Differentiation of Renal Cortical Neoplasms
US Issued Patent 8,603,948 US 14/078,726 Europe 08844570.5
Methods for Detecting Human Papilloma Virus-Associated Cancers
US 13/227,027 US 13/474,111 PCT/US2011/050681
Methods and Tools for the Diagnosis of Female Gynecological Cancers and Precancers
US 61/581,350
2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 36
BioServe India – Profile & Capabilities
Cutting-Edge Genomic Services:
Next Generation Sequencing, Genotyping & DNA Synthesis
Founded in 2002 and located in Hyderabad, Andhra Pradesh.
14,000 square foot NABL* accredited facility for its GMO services, equipped
with NGS capabilities.
33 employees including 19 scientific staff members and 7 in sales.
Has developed next generation sequencing panels for oncology.
Infrastructure and scientific expertise required to integrate CGI’s DNA-FISH
probe manufacturing and proprietary FHACT® business into the Indian
biotech market that accounts for >25% of global cervical cancer deaths.
Current customers include Center for Cellular and Molecular Biology, Center
for DNA Finger Printing and Diagnostics and Dr. Reddy's labs.
Backed by VenturEast, a pioneering healthcare-focused venture capital fund
manager based in India with ~$300 Million under management.
$65 Bn
$100 Bn
2013 2015
Indian Healthcare Sector
Dx & Medical Equipment
$3.3 Bn
$5 Bn
2013 2015
15-20%
Growth
Source: PM Live Pharmaceutical
Industry News & KPMG
*NABL: National Accreditation Board for Testing and Calibration Laboratories (equivalent to CLIA).